Evidence map›Paper›PMID 40292193›Full record

ArticleMedical research archives2024

Protease activity-based nanobiosensors for early detection of pancreatic cancer.

Obdulia Covarrubias-Zambrano, Deepesh Agarwal, Madumali Kalubowilage, Sumia Ehsan, Asanka S Yapa, Jose Covarrubias, Anup Kasi, Balasubramaniam Natarajan, Stefan H Bossmann

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical research archives, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Obdulia Covarrubias-ZambranoDepartment of Cancer Biology, University of Kansas Medical School, Kansas City, KS, USA.
Deepesh AgarwalDepartment of Electrical and Computer Engineering, Kansas State University, Manhattan, KS, US.
Madumali KalubowilageDepartment of Chemistry, Kansas State University, Manhattan, KS, USA.
Sumia EhsanDepartment of Chemistry, Kansas State University, Manhattan, KS, USA.
Asanka S YapaDepartment of Chemistry, Kansas State University, Manhattan, KS, USA.
Jose CovarrubiasDepartment of Cancer Biology, University of Kansas Medical School, Kansas City, KS, USA.
Anup KasiSchool of Medicine, University of Kansas Medical School, Kansas City, KS, USA.
Balasubramaniam NatarajanDepartment of Electrical and Computer Engineering, Kansas State University, Manhattan, KS, US.
Stefan H BossmannDepartment of Cancer Biology, University of Kansas Medical School, Kansas City, KS, USA.

Funding

Transgenic & Gene-Targeting Shared ResourceP30CA168524 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ROY A. JENSEN · 2012 to 2026
$40.1M
NCI NIH HHS P30 CA168524
6 · The paper itself

Abstract

Five-year survival rate for pancreatic cancer patients has increased to 12.8% afterthe initial diagnosis, still making it one of the deadliest cancertypes. This disease is known as the "silent killer" because early detection is challenging due to the location of the pancreas in the body and the nonspecific clinical symptoms. The Bossmann group has developed ultrasensitive nanobiosensors for protease/arginase detection comprised of Fe/Fe

Indexed as

biophotonicshierarchical decision structureiron/iron oxide nanoparticleliquid biopsyNanomedicinepancreatic cancer detection

Identifiers

PMID40292193
PMCPMC12031639

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.